1. Home
  2. PRG vs NVCR Comparison

PRG vs NVCR Comparison

Compare PRG & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

N/A

Current Price

$31.07

Market Cap

1.6B

ML Signal

N/A

Logo NovoCure Limited

NVCR

NovoCure Limited

N/A

Current Price

$15.88

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRG
NVCR
Founded
2020
2000
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Diversified Commercial Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
2.0B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
PRG
NVCR
Price
$31.07
$15.88
Analyst Decision
Strong Buy
Buy
Analyst Count
6
7
Target Price
★ $53.43
$27.14
AVG Volume (30 Days)
512.0K
★ 881.8K
Earning Date
10-21-2026
10-29-2026
Dividend Yield
★ 1.81%
N/A
EPS Growth
N/A
★ 21.79
EPS
★ 1.80
N/A
Revenue
★ $2,409,223,000.00
$655,353,000.00
Revenue This Year
$26.86
$10.76
Revenue Next Year
$7.61
$10.88
P/E Ratio
$17.49
★ N/A
Revenue Growth
N/A
★ 8.28
52 Week Low
$25.80
$9.82
52 Week High
$47.73
$21.45

Technical Indicators

Market Signals
Indicator
PRG
NVCR
Relative Strength Index (RSI) 20.18 47.89
Support Level $28.97 $14.93
Resistance Level $33.81 $18.43
Average True Range (ATR) 1.16 0.57
MACD -0.28 -0.02
Stochastic Oscillator 2.96 60.84

Price Performance

Historical Comparison
PRG
NVCR

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: